We have previously constructed vaccinia virus (VV) recombinants containing a complete or truncated envelope (env) gene of bovine leukemia virus (BLV). Only recombinants carrying the complete env gene (W-BLV2 and W-BLV3) expressed env glycoprotein on the surface of virus-infected cells and produced an antibody response in rabbits. In the present study, these W recombinants were used to immunize sheep prior to challenge with BLV-infected peripheral blood mononuclear cells. Both humoral and cell-mediated immunity were monitored in infected animals. Sheep inoculated with recombinants containing the complete env gene showed a CD4 response to a defined epitope of gp5l, but this response was absent 4 months postchallenge. Anti-gp5l antibodies appeared in animals inoculated with complete env 2 weeks after challenge, reached a peak at 4 weeks, and subsequently declined over 16 months. No CD4 response was recorded in animals inoculated with recombinants containing truncated env gene (VV-BLV1). BLV-infected control animals and those animals receiving W-BLV1 were slower to develop antibodies postchallenge, and the titers of anti-gp5l antibodies continued to increase over 16 months. Proviral DNA was detected by the polymerase chain reaction in the four groups at 6 weeks after challenge.
Enzootic bovine leukosis is a neoplastic disease in adult cattle and is caused by the exogenous retrovirus bovine leukemia virus (BLV) (18) . Infection is usually acquired by horizontal transmission of infected lymphocytes. Most infected animals (70%) develop lymphocytosis, and up to 10% go on to develop tumors (6) . The majority of infected animals remain clinically healthy and act as carriers for the spread of the disease (6) . On the other hand, sheep experimentally infected with BLV are highly susceptible to the oncogenic effects of the virus with a relatively short latency period (7, 16) , making the sheep a good model for vaccine-related studies.
Antibody response to the BLV surface glycoprotein gpSl is detected shortly after infection, but despite the persistence of anti-gpSl antibodies, the disease is progressive (4, 24) . Infected animals with lymphocytosis routinely have high titers of gpSl-specific antibodies. Although these antibodies have neutralizing activity against BLV in vitro, this finding has raised the possibility that nonhumoral mechanisms of immunity may play a major role in protection. Furthermore, we have recently defined CD4 and CD8 T-cell epitopes on BLV gp5l (8) late specific cellular immune responses may protect animals from BLV infection. Recently, a cell-derived vaccine producing BLV env gene glycoproteins and the core structural protein p24 was shown to protect cattle against BLVinduced leukemia (1) .
We and others have produced vaccinia virus (VV) recombinants which express the BLV env glycoproteins on the surface of infected cells (15, 21, 22, 25) . Seven from eight sheep vaccinated with these recombinants resisted a challenge with BLV-infected lymphocytes and possessed neutralizing antibodies to BLV (25) . On the other hand, while Ohishi et al. (22) reported protective immunity in sheep vaccinated with VV recombinants expressing BLV env, they failed to detect binding or neutralizing antibodies to BLV. This result further highlights the possibility that cellular immunity may be the critical form of immunity and that specific antibodies measured in some studies may simply be a marker of an (unmeasured) T-cell response. We report here a vaccine trial utilizing VV recombinants containing the complete or truncated form of the env gene of BLV MATERIALS AND METHODS Cells and viruses. VV-WR-L929 and VV-ELSTREE strains were used for the construction of recombinant viruses, and CV-1 cells were used for growth and maintenance of these recombinants (3) . Peripheral blood lymphocytes were separated from whole blood by Ficoll-Paque centrifugation.
Construction of recombinant viruses. The env gene of an Australian BLV provirus, isolated from a cow tumor, was released as a 2.33-kb XhoI fragment (nucleotides 4554 to 6886 [5] ) and cloned into the SalI site of pUC8. From this clone, three VV plasmid vectors, pSK26, pSK27, and pSK29, were constructed as described by Kumar et al. (15) . Three recombinants (VV-BLV1, VV-BLV2, and VV-BLV3) were derived from pSK26, pSK27, and pSK29, respectively. VV-BLV1 (truncated form) contained the coding sequence for gpSl and part of gp3O (nucleotides 4813 to 6124). VV-BLV2 and VV-BLV3 contained the entire env gene of BLV under the control of promoters isolated from VV (P7.5) and fowlpox virus (PFE/L), respectively. The latter constructs are referred to as complete env.
Animals. Sheep (6 months old) were divided into four groups. Ten animals in group I were used for vaccination with VV-BLV1. Group II contained six sheep vaccinated with VV-BLV2. Group III (six animals) was vaccinated with VV-BLV3, and seven animals (group IV) were left unvaccinated as controls for challenge. Immunized groups were housed in fully screened, separate pens provided with isolated drainage, and the controls (unimmunized sheep) were kept isolated from vaccinated groups in a separate building.
Immunization and challenge of sheep. Groups I, II, and III were injected intradermally with 2 x 108 PFU of recombinant viruses VV-BLV1, VV-BLV2, and VV-BLV3, respectively. A booster dose of the same amount was administered once, 2 weeks after the initial vaccination. Vaccinated animals were challenged 5 weeks after inoculation with whole blood containing 4 x 104 PBMCs from a BLV-infected cow at the persistent lymphocytosis stage (80% lymphocytes). Blood samples were collected after the initial and booster inoculations, every 2 weeks for 8 weeks postchallenge, and at monthly intervals as indicated for DNA extraction, antibody measurement, cell-mediated response, and hematology.
DNA extraction. Chromosomal DNA was extracted from PBMCs according to the method of Miller et al. (19) . Briefly, cells were lysed with nuclei lysis buffer (10 mM Tris-HCl, 400 mM NaCl, 2 mM EDTA [pH 8.2]). The cell lysates were digested overnight at 37°C with 0.2 ml of 10% sodium dodecyl sulfate (SDS) and 0.5 ml of a proteinase K solution (1 mg in 1% SDS-2 mM EDTA). After digestion, 1 ml of 6 M NaCl was added to remove protein, and DNA was precipitated with 2 volumes of ethanol and dissolved in 10 mM Tris-HCl-0.2 mM EDTA (pH 7.5). DNA concentration was estimated by measuring the A260.
PCR. PCR was used to assay for the presence of proviral DNA in circulating blood of sheep immunized with VV recombinants, using oligonucleotide primers from the env gene as described previously (20) . Another set of oligonucleotide primers for the pol gene was used for detection of BLV provirus in vaccinated animals every 2 weeks up to 8 weeks after challenge and at monthly intervals thereafter. These primers extended from sequence positions 2352 to Agar gel immunodiffusion test. Serum samples from all sheep were tested for BLV gpSl antibodies by using the agar gel immunodiffusion test (Leukassy-B; Pitman-Moore, Washington Crossing, N.J.). The gpSl antibody titers in the sera were determined biweekly until 8 weeks after challenge and then at intervals as indicated.
Hematology. Venous blood samples for total and differential leukocyte counts were collected at the following times: before initial vaccination, at biweekly intervals after initial vaccination until 8 weeks after challenge, and subsequently at monthly intervals throughout the observation period.
Peptide synthesis. Peptides corresponding to the BLV gpSl protein sequences were synthesized manually by the multiple peptide procedure (13) . A series of 26 peptides (20 amino acids in size and overlapping by 10 amino acids) was prepared. Mapping of proliferation and cytotoxic T-lymphocyte (CTL) epitopes on BLV gp5l molecules by using these peptides has been described elsewhere (8) .
Lymphocyte proliferation assay. The proliferation assay was performed as described previously (10) . Briefly, 2 x 105 PBMC per well were cultured in RPMI 7 days of incubation at 37°C with 5% CO2, the cells were pulsed with 0.5 ,uCi of [methyl-3H]thymidine (Amersham) per well in a volume of 20 ,ul for 16 h. The cells were harvested, and proliferation was estimated by liquid scintillation counting. The proliferation was expressed as a stimulation index (SI = cpm in tested sample/cpm in control wells). The response to any concentration was considered positive if the SI was greater than 2.
Generation and assay of CTL. The assay used to measure the CD8 cytolytic activity was that described previously (12) . Briefly, mononuclear cells (3 x 106) were cultured in the presence of 10 ,ug of synthetic peptide per ml for 8 to 10 days, with human interleukin-2 (50 U/ml) added on day 2.
Next, 106 cells were restimulated in secondary culture with 9 x 106 irradiated (2.5 Gy) autologous mononuclear cells in the presence of peptide and interleukin-2 for 5 days. Autologous fresh target PBMCs (3 x 106), stimulated with phytohemagglutinin for 3 days, were incubated overnight with individual peptides or groups of peptides and then labeled with 100 pCi of Na251CrO4 (Amersham) (15) .
A vaccine trial was conducted in sheep inoculated twice intradermally with 2 x 108 PFU of the VV recombinants (VV-BLV1, VV-BLV2, and VV-BLV3). Five weeks after vaccination, all groups were challenged intravenously with 4 x 104 lymphocytes from a cow with persistent lymphocytosis. The challenge dose was based on previous data from this laboratory which showed that as few as 200 lymphocytes were effective in causing infection in sheep (9) .
Hematological responses. After initial immunization, the mean lymphocyte counts for VV-BLV2 and VV-BLV3 groups were significantly higher than those of VV-BLV1 (P < 0.05) and control (P < 0.01) groups (Fig. 1) . After booster inoculation, the mean lymphocyte counts of the VV-BLV2
and VV-BLV3 groups were still significantly higher (P < 0.05 and P < 0.01, respectively) than those in the VV-BLV1 and control groups. This increase occurred prior to BLV gpSl antibody appearance in the vaccinated sheep. The peripheral blood lymphocyte counts returned to low levels following challenge and remained so throughout the observation period of 16 months (Fig. 1) .
Humoral response to BLV. Antibodies against gpSl antigen were not detected in vaccinated animals prior to challenge (Table 2) . Two weeks after challenge, anti-gpSl antibodies were observed in the two groups inoculated with recombinants containing complete env, VV-BLV2 and VV-BLV3.
Antibody levels reached a peak by 4 to 6 weeks postchallenge, declined, and remained at low levels over a period of Fig. 2A and 3A , respectively. These results were confirmed by DNA hybridization using a BLV DNA probe ( Fig.  2B and 3B) . It was not possible to detect proviral DNA in the animals vaccinated with either VV-BLV2 or VV-BLV3 by 4 months postinfection or for the remainder of the trial. In contrast, an amplified fragment was detected throughout the trial period for the majority of animals in the VV-BLV1 and control infected groups. The results in Fig. 4 at 16 months postinfection demonstrate that 8 of 10 animals in the VV-BLV1 group were positive, as were all of the control infected group, whereas provirus was not detected in any of the animals in the VV-BLV2 and VV-BLV3 groups.
Detection of BLV infectivity in immunized sheep. To confirm the vaccine-mediated protection suggested by PCR, PBMCs (106 cells) from all animals in the four groups were used to inoculate recipient seronegative sheep at 2 years postimmunization. All sheep inoculated with PBMCs from the control infected group (7 of 7) and the VV-BLV1 group (10 of 10) had anti-gp5l antibodies 4 to 6 weeks following inoculation. Over an observation period of 10 weeks, none of six animals in the VV-BLV2 group seroconverted, and only two of six in the VV-BLV3 group seroconverted. Cell-mediated response. We have recently used synthetic peptides to identify a proliferative (CD4) and a cytotoxic (CD8) epitope of the gpSl antigen of BLV (8) . Peptide 51-70 was used in this study to assay for proliferative response, and peptide 131-150 was used to assay for CTL in sheep exposed to BLV.
(i) CD4 response. CD4 epitope-induced proliferation was observed in all of the sheep immunized with VV-BLV2 or VV-BLV3 immunogens and in only one of seven in the control group when the animals were tested at 3 weeks after booster inoculations (Table 3 ). The highest SIs were up to 11 at peptide concentrations of 2.5 and 5.0 ,ug/ml ( Table 3 ). The appearance of the CD4 T-cell proliferation responses in the PBMCs of these sheep occurred before BLV gpSl antibodies could be detected by the agar gel immunodiffusion test. In contrast, individuals immunized with VV-BLV1 immunogen did not exhibit any specific proliferation following immunization. In these sheep, the SI values were usually less than 2 when tested with any peptide concentration ( Table 3) . None of the sheep in any of the groups responded to peptide (SI < 2) following challenge (Table 4) .
(ii) CD8 response. We intended to assess the role of CD8 
DISCUSSION
In this study, we have demonstrated that VV recombinants containing the complete env gene induce peptide 51-70-specific CD4 T-cell responses and antibody responses in sheep. Following challenge, the majority (10 of 12) of these animals were protected against infection, as determined by antibody response, PCR, and infectivity of PBMCs in recipient animals. The two positive animals in the VV-BLV3 group might be explained by the use of a fowlpox virus promoter (PFE/L) in that particular construct compared with the VV P7.5 promoter in the VV-BLV2 construct. The absence of antibodies in a previously successful vaccinia vaccination study together with the results of this study strongly suggest that cellular immunity is critical for protection. The correlation that we report here between protection and T-cell responses to peptide 51-70 is the most precise correlation of protection yet defined. This trial was more extensive and monitored for a considerably longer time period than was the case in two other recent trials with VV-BLV constructs (22, 25) . Persistence of anti-p24 antibodies and a decrease in antibodies against gpSl, accompanying protection, were reported for sheep inoculated with VV recombinants containing gpSl and gp3O (25) . A similar pattern was observed in the present study; antibodies against gpSl reached a maximum in the first 4 weeks after challenge, decreased by 8 weeks, and remained at low levels for the duration of the trial. In contrast in uninoculated sheep and in those inoculated with truncated env (VV-BLV1), anti-gpSl antibodies were somewhat slower to appear after challenge and continued to rise for the duration of the 16-month trial. A gradual fall in antibody titers has also been observed to accompany protection in human immunodeficiency virusinfected chimpanzees immunized with recombinant human immunodeficiency virus env gpl20 (2) and in macaques, in which antibodies to simian immunodeficiency virus increased postchallenge and subsequently declined (26 than in controls postchallenge, as was observed in this study. However, the antibody response in control and VV recombinant-inoculated animals did not differ much at 26 weeks postchallenge in their study. They concluded that humoral immunity is unlikely to play a major role in protection against BLV, since inoculation with VV recombinants containing env did not induce a detectable antibody response, inoculation suppressed the growth of BLV with virtually no effect on antibody response, and antibody titers did not correlate with extent of BLV proliferation. On the other hand, sheep passively immunized with anti-BLV antibodies, provided they had high titers of anti-gpSl antibodies, successfully resisted infection with virus (14) . In addition, gpSl glycoprotein can induce neutralizing activity against BLV and protect sheep against infection (23) . The data presented here and those of Portetelle et al. (25) point to the importance of high titers of neutralizing antibodies at early stages after challenge, with less reliance on humoral immunity over longer periods.
Ohishi et al. (22) suggested that cell-mediated immune response played a major role in the suppression of BLV proliferation. This contention is based on the observation that inoculation of sheep with VV recombinants induces a strong delayed-type hypersensitivity response and stimulates helper T cells, as deduced from the memory effect for antibody response. In that study, the composition of cells infiltrating skin lesions in the delayed-type hypersensitivity response was 25% CD4 and 65% CD8 48 h after challenge. The results described in the present study also support a role for cell-mediated immunity in protection against BLV infection. All of those animals inoculated with VV-BLV2 and VV-BLV3 showed a proliferative response to a peptide derived from gp5l which we have shown to be a CD4+ T-cell epitope (8) .
It is interesting to observe that animals infected with VV-BLV1 do not generate helper CD4 T-cell responses. The evidence for this conclusion comes The early appearance of anti-gpSl antibodies in sheep inoculated with VV-BLV2 and VV-BLV3 could be due to the presence of these helper T cells. On the other hand, only one of seven control sheep showed a response, and none of the animals inoculated with VV-BLV1 responded. The response to gpSl peptide was lost at 4 months after challenge and may indicate that loss of immunological memory occurs with loss of gpSl antigen. This would support the observation in mice that T-cell memory requires antigenic persistence (11) .
In summary, we have described an extensive vaccine trial in sheep which demonstrates that presentation of the major surface BLV antigen gp5l in a configuration mimicking that of its native state provides protection against infection with this virus in sheep. While a humoral response may play some role in protection, it is likely that a cell-mediated response also contributes to protection. The CD4 T-cell response to peptide 51-70 correlates with protection, and a synthetic peptide vaccine based on this sequence may prevent BLV in animals at risk. Furthermore, BLV may provide a model for vaccine design for human leukemia mediated by the related virus human T-cell leukemia virus type I.
